Open AccessArticle
Wearable Telemonitoring in Focal Spasticity: A Prospective Exploratory Pilot Study of Daily-Life Mobility Monitoring
by
Theodoros Saganas, Spyridon Votis, Fotios Kantas, Foivos S. Kanellos, Georgios Rigas, Andreas P. Katsenos, Yannis V. Simos, Lampros Lakkas, Georgios S. Markopoulos, Vasiliki Kostadima, Spyridon Konitsiotis, Dimitrios Peschos and Konstantinos I. Tsamis
Viewed by 710
Abstract
Spasticity is a common and disabling consequence of upper motor neuron lesions, and its follow-up relies largely on clinical scales that may not fully reflect daily-life mobility. This prospective single-arm exploratory pilot study examined wearable-derived daily-life mobility metrics around a scheduled botulinum neurotoxin
[...] Read more.
Spasticity is a common and disabling consequence of upper motor neuron lesions, and its follow-up relies largely on clinical scales that may not fully reflect daily-life mobility. This prospective single-arm exploratory pilot study examined wearable-derived daily-life mobility metrics around a scheduled botulinum neurotoxin type A (BoNT-A) injection cycle and assessed their associations with established clinical measures. Thirteen patients with focal spasticity secondary to stroke (
n = 11) or multiple sclerosis (
n = 2) underwent baseline and 6-week follow-up assessment using the Modified Ashworth Scale (MAS), Motricity Index (MI), the Timed Up and Go test (TUG) and a multi-sensor wearable monitoring system. Device-derived outcomes included gait impairment, gait speed, stride length, angular velocity, and lack of movement. Clinical scales generally changed in the expected post-treatment direction, with reduced MAS scores and descriptive or directional improvements in MI scores and TUG performance. Wearable metrics captured descriptive changes in daily mobility, notably a reduction in lack of movement. Furthermore, in exploratory pooled analyses, selected gait-related metrics tended to be associated with TUG performance and lower-extremity MAS. These findings highlight the potential of wearable telemonitoring to complement conventional clinical scales by providing objective, real-world data, supporting its further validation as a tool for longitudinal spasticity management and neurorehabilitation. These device-derived metrics should be interpreted as mobility-related digital biomarkers rather than direct surrogate measures of spasticity.
Full article
►▼
Show Figures